SEC 13F Intelligence

Casdin Capital, LLC / ABCL

Casdin Capital, LLC’s Abcellera Biologics Inc Position

Does Casdin Capital, LLC own Abcellera Biologics Inc (ABCL)? Not currently — the last reported position was 2.36M shares worth $11M in Q1 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$11M
Q1 2024
Shares
2.36M
% of Portfolio
+0.79%
Quarters Held
9
position exited

Position History ABCL

Reported value by quarter
Q4 ’20: $8MQ4 ’20Q2 ’22: $8MQ3 ’22: $16MQ3 ’22Q4 ’22: $23MQ1 ’23: $19MQ1 ’23Q2 ’23: $16MQ3 ’23: $11MQ3 ’23Q4 ’23: $13MQ1 ’24: $11MQ1 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20242.36M$11M+0.79%
Q4 20232.36M$13M+1.32%
Q3 20232.36M$11M+1.20%
Q2 20232.52M$16M+1.42%
Q1 20232.52M$19M+1.57%
Q4 20222.27M$23M+1.78%
Q3 20221.65M$16M+1.07%
Q2 2022750.0K$8M+0.68%
Q4 2020200.0K$8M+0.24%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Casdin Capital, LLC’s full portfolio or all institutional holders of ABCL.